For 2024, includes $47.9 million related to goodwill impairment. For the three months ended September 30, 2023, includes a $16.2 million impairment loss on lab equipment and a $96.2 million impairment ...

To say that Ginkgo Bioworks' (NYSE: DNA) stock is in a bit of a rough patch doesn't quite capture it. With the price of its shares down by 81% in 2024 alone, many investors are likely wishing they had ...

BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to ...

BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, announced that in connection to its transaction with ...

The most ambitious part of Ginkgo's vision is to become a large-scale and hyperefficient manufacturer of bioengineered organisms, proteins, other biomolecules -- and laboratory data. It hopes to serve ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Amid layoffs and a disintegrating share ...

Let's begin with why the market has been so bearish on this business lately. This May, Ginkgo announced that it will be cutting its labor costs by around 25%, which translates to letting go of more ...

BOSTON, Aug. 1, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to ...